RxDoctor Payments Data

Brooke Veer Sundermeier, APRN

Acute Care · Bend, ORNPI 1649757436

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $679 of the $779 with a category attached, or 87.2%. It is spread thinly across 11 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $487, 3.3 times the $149 reported in 2023.

$779in general payments, 2019–2025

Across 21 payments — averaging $37.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$136
  • AbbVie$132
  • Coloplast$125
  • Sumitomo Pharma America, Inc.$103
  • Progenics Pharmaceuticals, Inc.$61
  • Urogen Pharma, Inc.$55
  • plus $169 from 5 others

What the payments were for

  • Food & beverage$67987%
  • Education$10013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$779 in reported general payments places this provider in the 70th percentile of 105 acute care providers in Oregon.

See all acute care providers in Oregon

Medicare billing

Part B allowed, 2024
$62,815
Medicare patients
387
Services billed
3,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron63$34,772
GemtesaVibegron51$34,287
Tamsulosin Hcl178$3,938
Estradiol33$1,965
Trospium Chloride31$1,143
Testosterone Cypionate24$907
Finasteride59$869
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst26$292
Atorvastatin Calcium16$287
Alfuzosin Hcl ErAlfuzosin Hcl13$181
Lisinopril14$105
Cephalexin30$102
Ciprofloxacin Hcl31$98
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$103$34,28751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 105 acute care providers in Oregon.

Other acute care in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →